Abstract
“Tissue” or type 2 Transglutaminase (TG2) is a peculiar multifunctional enzyme able to catalyse Ca2+-dependent posttranslational modification of proteins, by establishing covalent bonds between peptide-bound glutamine residues and either lysine residues or mono- and poly-amines. In addition, it may act also as a G protein in transmembrane signalling, as a kinase, as a protein disulphide isomerase and as a cell surface adhesion mediator. The vast array of biochemical functions exerted by TG2 characterises and distinguishes it from all the other members of the transglutaminase family. Multiple lines of evidence suggest an involvement of the enzyme in neurodegenerative diseases, such as Huntingtons (HD) and Parkinson (PD), and that its inhibition, either via drug treatments or genetic approaches, might be beneficial for the treatment of these syndromes. This review will exploit the recent developments in the comprehension of the role played by type 2 transglutaminase in eukaryotic cells, focusing on the role exerted by TG2 on mitochondrial physiology and on the regulation of cell death pathways at the basis of neurodegenerative diseases.
Current Pharmaceutical Design
Title: Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Volume: 14 Issue: 3
Author(s): Mauro Piacentini, Walter Malorni, Maria Grazia Farrace and Carlo Rodolfo
Affiliation:
Abstract: “Tissue” or type 2 Transglutaminase (TG2) is a peculiar multifunctional enzyme able to catalyse Ca2+-dependent posttranslational modification of proteins, by establishing covalent bonds between peptide-bound glutamine residues and either lysine residues or mono- and poly-amines. In addition, it may act also as a G protein in transmembrane signalling, as a kinase, as a protein disulphide isomerase and as a cell surface adhesion mediator. The vast array of biochemical functions exerted by TG2 characterises and distinguishes it from all the other members of the transglutaminase family. Multiple lines of evidence suggest an involvement of the enzyme in neurodegenerative diseases, such as Huntingtons (HD) and Parkinson (PD), and that its inhibition, either via drug treatments or genetic approaches, might be beneficial for the treatment of these syndromes. This review will exploit the recent developments in the comprehension of the role played by type 2 transglutaminase in eukaryotic cells, focusing on the role exerted by TG2 on mitochondrial physiology and on the regulation of cell death pathways at the basis of neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Piacentini Mauro, Malorni Walter, Farrace Grazia Maria and Rodolfo Carlo, Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection, Current Pharmaceutical Design 2008; 14 (3) . https://dx.doi.org/10.2174/138161208783413220
DOI https://dx.doi.org/10.2174/138161208783413220 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension and Ischemic Heart Disease in Women
Current Pharmaceutical Design The Janus Face of Adenosine: Antiarrhythmic and Proarrhythmic Actions
Current Pharmaceutical Design High Serum Alkaline Phosphatase Levels in Relation to Multi-Cerebral Microbleeds in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Effects of Anesthetics on Mitochondrial Signaling and Function
Current Drug Safety Free Fatty Acids: Circulating Contributors of Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Mechanisms And Prevention Of TAVI-Related Cerebrovascular Events
Current Pharmaceutical Design Targeting Protein-Protein Interactions in the Proteasome Super-Assemblies.
Current Topics in Medicinal Chemistry Effects of Obesity on Vascular Potassium Channels
Current Vascular Pharmacology Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Store-Dependent Ca2+ Entry in Endothelial Progenitor Cells As a Perspective Tool to Enhance Cell-Based Therapy and Adverse Tumour Vascularization
Current Medicinal Chemistry Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design Immunomodulatory Properties of Farnesoids: The New Steroids?
Current Medicinal Chemistry The L-Type Ca2+ Channel as a Therapeutic Target in Heart Disease
Current Medicinal Chemistry Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases
Current Pharmaceutical Design Pathogenesis of Age-Related Cataract: A Systematic Review of Proteomic Studies
Current Proteomics Integrating Coronary Calcium into Risk Prediction: Current Approaches and Future Directions
Current Cardiology Reviews Recent Advances in Ethnopharmacological and Toxicological Properties of Bioactive Compounds from <i>Aloe barbadensis</i> (Miller), <i>Aloe vera</i>
Current Bioactive Compounds Acid-Sensing Ion Channels: A Novel Therapeutic Target for Pain and Anxiety
Current Pharmaceutical Design Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Stem Cell Therapies for Ischemic Cardiovascular Diseases
Recent Patents on Regenerative Medicine